Androgen receptor signaling inhibitors have a metastasis-free survival benefit for men with nonmetastatic castration-resistant prostate cancer. The latest updates for the PROSPER, SPARTAN, and ARAMIS trials also demonstrate an overall… Click to show full abstract
Androgen receptor signaling inhibitors have a metastasis-free survival benefit for men with nonmetastatic castration-resistant prostate cancer. The latest updates for the PROSPER, SPARTAN, and ARAMIS trials also demonstrate an overall survival benefit. However, the cardiovascular toxicity associated with prolonged use of these agents should be taken into consideration before initiating therapy.
               
Click one of the above tabs to view related content.